


Author's Accepted Manuscript

Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons from Chronic Myelogenous Leukemia (CML)

Musa Yilmaz MD, Elias Jabbour MD



www.elsevier.de/ending

PII: S0093-7754(15)00200-6
DOI: <http://dx.doi.org/10.1053/j.seminoncol.2015.09.030>
Reference: YSONC51886

To appear in: *Semin Oncol*

Cite this article as: Musa Yilmaz MD, Elias Jabbour MD, Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons from Chronic Myelogenous Leukemia (CML), *Semin Oncol*, <http://dx.doi.org/10.1053/j.seminoncol.2015.09.030>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons from Chronic Myelogenous Leukemia (CML)

Musa Yilmaz, MD¹, Elias Jabbour, MD²

¹Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX

²Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Corresponding Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Box 428, 1515 Holcombe Blvd., Houston, TX 77030. E-mail: ejabbour@mdanderson.org, Tel. 713-792-4764, Fax 713-792-0319

Research support from Ariad and Teva.

Conflict of Interest:

Elias Jabbour: Consultancy from BMS, Ariad, Pfizer, and Teva. Musa Yilmaz: nothing to disclose

Download English Version:

<https://daneshyari.com/en/article/10924318>

Download Persian Version:

<https://daneshyari.com/article/10924318>

[Daneshyari.com](https://daneshyari.com)